- Home
- IBTA vs HROW Comparison
IBTA vs HROW Comparison
Compare IBTA & HROW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IBTA
- HROW
- Stock Information
- Founded
- IBTA 2011
- HROW 1998
- Country
- IBTA United States
- HROW United States
- Employees
- IBTA N/A
- HROW N/A
- Industry
- IBTA
- HROW Biotechnology: Pharmaceutical Preparations
- Sector
- IBTA
- HROW Health Care
- Exchange
- IBTA Nasdaq
- HROW Nasdaq
- Market Cap
- IBTA 1.6B
- HROW 1.9B
- IPO Year
- IBTA 2024
- HROW N/A
- Fundamental
- Price
- IBTA $67.03
- HROW $38.90
- Analyst Decision
- IBTA Strong Buy
- HROW Strong Buy
- Analyst Count
- IBTA 9
- HROW 4
- Target Price
- IBTA $89.67
- HROW $55.00
- AVG Volume (30 Days)
- IBTA 277.7K
- HROW 696.6K
- Earning Date
- IBTA 11-13-2024
- HROW 11-13-2024
- Dividend Yield
- IBTA N/A
- HROW N/A
- EPS Growth
- IBTA N/A
- HROW N/A
- EPS
- IBTA 0.48
- HROW N/A
- Revenue
- IBTA $368,548,000.00
- HROW $169,138,000.00
- Revenue This Year
- IBTA $19.37
- HROW $58.50
- Revenue Next Year
- IBTA $20.75
- HROW $48.62
- P/E Ratio
- IBTA $138.40
- HROW N/A
- Revenue Growth
- IBTA 74.91
- HROW 48.15
- 52 Week Low
- IBTA $41.87
- HROW $8.26
- 52 Week High
- IBTA $110.95
- HROW $59.23
- Technical
- Relative Strength Index (RSI)
- IBTA N/A
- HROW 35.91
- Support Level
- IBTA N/A
- HROW $38.96
- Resistance Level
- IBTA N/A
- HROW $54.19
- Average True Range (ATR)
- IBTA 0.00
- HROW 2.83
- MACD
- IBTA 0.00
- HROW -0.78
- Stochastic Oscillator
- IBTA 0.00
- HROW 14.77
About IBTA Ibotta Inc. Class A Common Stock
Ibotta Inc is a performance marketing platform. It allows CPG brands to deliver digital promotions to consumers through a single, convenient network called the Ibotta Performance Network (IPN).
About HROW Harrow Inc.
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company helps U.S. eyecare professionals preserve the gift of sight by making its comprehensive portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of Americans.